8-K: OraSure Q4 2025: Revenue Below Guidance, New Tests Submitted

OraSure Technologies reported a 29% decrease in Q4 2025 total net revenues to $26.8 million, while submitting two key product applications to the FDA for regulatory clearance.

Summary

• Total net revenues for the fourth quarter of 2025 decreased 29% to $26.8 million from $37.4 million in the fourth quarter of 2024.
• Core revenues (excluding COVID-19, Molecular Services, and Risk Assessment Testing) of $26.7 million in Q4 2025 decreased 22% year-over-year.
• Diagnostics revenues in Q4 2025 decreased 20% year-over-year to $15.1 million, primarily due to lower revenue from HIV tests.
• Sample Management Solutions revenues in Q4 2025 decreased 39% year-over-year to $9.1 million, mainly attributable to a large customer in the consumer genomics segment.
• GAAP gross margin improved to 41.0% in Q4 2025 from 36.2% in Q4 2024, and Non-GAAP gross margin improved to 41.4% from 40.1%.
• GAAP operating loss for Q4 2025 was $20.1 million, compared to $12.4 million in Q4 2024.
• GAAP net loss for Q4 2025 was $19.3 million, compared to $10.8 million in Q4 2024.
• Cash and cash equivalents were $199 million as of December 31, 2025.
• OraSure deployed $5 million during Q4 2025 to repurchase approximately 1.9 million shares of common stock.
• Submitted applications to the U.S. FDA in December 2025 for clearance of a rapid molecular self-test for Chlamydia and Gonorrhoeae (CT/NG) and a Colli-Pee at-home urine collection device for sexually transmitted infections (STIs).
• Received a license from Health Canada authorizing the use of the OraQuick HIV Self-Test in Canada.
• The company is guiding to Q1 2026 total revenues of $26 million to $29 million, with negligible COVID-19 testing revenues.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue was above guidance midpoint and gross margins improved, the significant year-over-year revenue decline and increased net losses, coupled with negative operating cash flow, indicate ongoing challenges. However, the progress on new product submissions and a strong cash balance provide a basis for future growth.

Positives

• Q4 2025 total revenue of $26.8 million was above the midpoint of the company's guidance range.
• GAAP gross margin improved to 41.0% in Q4 2025 from 36.2% in Q4 2024, indicating better cost management or product mix.
• Non-GAAP gross margin improved to 41.4% in Q4 2025 from 40.1% in Q4 2024.
• Submitted two significant product applications (rapid molecular self-test for CT/NG and Colli-Pee at-home urine collection device for STIs) to the FDA in December 2025, with anticipated U.S. regulatory clearance and launches in 2026.
• Received Health Canada license for the OraQuick HIV Self-Test, expanding international market access.
• Maintained a strong balance sheet with $199 million in cash and no debt as of December 31, 2025.
• Continued execution of the $40 million share repurchase program, deploying $5 million in Q4 2025 to repurchase approximately 1.9 million shares.
• Management expresses confidence in returning to growth in 2026 and observes increasing signs of stability in key segments.
• Identified a path to 50% adjusted gross margin with significant expansion opportunities as volumes grow.

Negatives

• Total net revenues decreased significantly by 29% year-over-year in Q4 2025 to $26.8 million.
• Core revenues decreased 22% year-over-year in Q4 2025 to $26.7 million.
• Diagnostics revenues declined 20% year-over-year in Q4 2025, primarily due to lower HIV test revenue.
• Sample Management Solutions revenues decreased 39% year-over-year in Q4 2025, largely due to a major customer in consumer genomics.
• COVID-19 related revenues saw a drastic decline of 95% in Q4 2025 and 99% for the full year 2025.
• Risk Assessment Testing and Molecular Services revenues were negligible or zero in Q4 2025, indicating discontinuation or severe reduction.
• GAAP operating loss increased to $20.1 million in Q4 2025 from $12.4 million in Q4 2024.
• Non-GAAP operating loss increased to $15.2 million in Q4 2025 from $6.7 million in Q4 2024.
• GAAP net loss increased to $19.3 million in Q4 2025 from $10.8 million in Q4 2024.
• Non-GAAP net loss increased to $13.6 million in Q4 2025 from $4.2 million in Q4 2024.
• Diluted GAAP EPS worsened to $(0.27) in Q4 2025 from $(0.14) in Q4 2024.
• Diluted Non-GAAP EPS worsened to $(0.19) in Q4 2025 from $(0.06) in Q4 2024.
• Net cash used in operating activities for FY 2025 was $(49.0) million, a significant reversal from $27.4 million provided in FY 2024.
• Total assets decreased from $479.7 million at December 31, 2024, to $403.2 million at December 31, 2025.
• Stockholders' equity decreased from $410.3 million at December 31, 2024, to $340.8 million at December 31, 2025.

Risks

• Ability to satisfy customer demand.
• Ability to reduce spending rate, capitalize on manufacturing efficiencies, and drive profitable growth.
• Ability to market and sell products and services, including through third parties.
• Failure of distributors or other customers to meet purchase forecasts or minimum purchase requirements.
• Significant customer concentrations that exist or may develop.
• Ability to manufacture products in accordance with applicable specifications, performance standards, and quality requirements.
• Ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications.
• Ability to comply with applicable regulatory requirements and effectively resolve warning letters, audit observations, or other findings from regulators.
• Changes in relationships, including disputes, with strategic partners and reliance on them for critical activities.
• Impact of replacing distributors.
• Inventory levels at distributors and other customers.
• Ability to achieve financial and strategic objectives and increase revenues, including expanding international sales.
• Impact of competitors, competing products, and technology changes.
• Reduction or deferral of public funding available to customers.
• Competition from new or better technology or lower cost products.
• Ability to develop, commercialize, and market new products.
• Market acceptance of products and services.
• Ability to achieve the anticipated benefits from the BioMedomics transaction.
• Changes in market acceptance of products based on performance or changes in testing guidelines, algorithms, or recommendations by agencies like the CDC.
• Ability to fund research and development and other products and operations.
• Ability to obtain and maintain new or existing product distribution channels.
• Reliance on sole supply sources for critical products and components.
• Availability of related products produced by third parties or products required for use of OraSure's products.
• Impact of contracting with the U.S. government.
• Impact of negative economic conditions.
• Ability to achieve and maintain sustained profitability and increase gross margins.
• Ability to utilize net operating loss carry forwards or other deferred tax assets.
• Volatility of stock price.
• Uncertainty relating to patent protection and potential patent infringement claims.
• Uncertainty and costs of litigation relating to patents, trade secrets, and other intellectual property.
• Availability of licenses to patents or other technology.
• Ability to enter into international manufacturing agreements and obstacles to international marketing and manufacturing.
• Impact of changes in international funding sources and testing algorithms on international sales.
• Adverse movements in foreign currency exchange rates.
• Loss or impairment of sources of capital.
• Ability to attract and retain qualified personnel.
• Exposure to product liability and other types of litigation.
• Changes in international, federal, or state laws and regulations.
• Customer consolidations and inventory practices.
• Equipment failures and ability to obtain needed raw materials and components.
• Cybersecurity incidents and other disruptions involving computer systems or those of third-party IT service providers, suppliers, and customers.
• Impact of terrorist attacks, civil unrest, hostilities, and war.
• General political, business, and economic conditions, including interest rates, inflationary pressures, capital market disruptions, changes in governmental agencies, international tariffs, trade protection measures, economic sanctions, and economic slowdowns or recessions.

Future Outlook

OraSure Technologies is guiding to Q1 2026 total revenues of $26 million to $29 million, which includes a negligible amount of COVID-19 testing revenues. Management is confident in returning to growth in 2026, supported by anticipated U.S. regulatory clearance and launches of its rapid molecular self-test for Chlamydia and Gonorrhoeae and the Colli-Pee at-home urine collection device for sexually transmitted infections. The company also anticipates a path to 50% adjusted gross margin with significant expansion as volumes grow.

Management Comments

• "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range." Carrie Eglinton Manner, President and CEO.
• "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." Carrie Eglinton Manner, President and CEO.
• "We are confident that OTI is positioned to return to growth in 2026, supported by anticipated U.S. regulatory clearance and launches of our rapid molecular self-test for Chlamydia and Gonorrhoeae and our Colli-Pee at-home urine collection device for sexually transmitted infections." Carrie Eglinton Manner, President and CEO.
• "We are making meaningful progress on our innovation roadmap and executing on our strategy to decentralize diagnostics and connect people to care that is more accessible, convenient, affordable, and private." Carrie Eglinton Manner, President and CEO.
• "Additionally, our strong balance sheet allows us to make disciplined investments in value-enhancing organic and inorganic opportunities while prudently returning capital to shareholders through our $40 million share repurchase program which we continue to execute." Carrie Eglinton Manner, President and CEO.

Industry Context

StockSavvy.ai notes that OraSure's focus on decentralizing diagnostics and at-home testing aligns with broader industry trends towards more accessible and convenient healthcare solutions, particularly in the STI and consumer genomics segments. The decline in COVID-19 related revenue is consistent with the overall market shift away from pandemic-driven demand, while the challenging funding environment in 2025 reflects broader economic pressures impacting healthcare spending.

Corporate Governance

Stakeholder Impact

• Shareholders: Negative impact from declining revenues and increased losses, but potential positive impact from the ongoing share repurchase program and future product launches.
• Customers: Expanded access to testing with new product clearances (e.g., OraQuick HIV Self-Test in Canada) and anticipated future devices (CT/NG, Colli-Pee).
• Employees: 'Org right-sizing' and 'reduced headcount' were mentioned as part of cost productivity efforts, indicating potential past or ongoing impact on the workforce.

Next Steps

• Anticipated U.S. regulatory clearance and launches of rapid molecular self-test for Chlamydia and Gonorrhoeae in 2026.
• Anticipated U.S. regulatory clearance and launches of Colli-Pee at-home urine collection device for STIs in 2026.
• The company will host a conference call and audio webcast on February 25, 2026, at 5 p.m. Eastern Time to discuss results and business developments.
• Investors should monitor the Investor Relations Section of OTI's website for material non-public information and Regulation FD compliance.

Key Dates

Recommendation

OraSure Technologies faces significant revenue declines and increased losses, indicating ongoing operational challenges. However, the company's strong cash position, active share repurchase program, and pipeline of new product submissions (especially for CT/NG and Colli-Pee) offer potential catalysts for future growth. The Q4 revenue exceeding guidance midpoint and improved gross margins are positive signs. A 'hold' recommendation is appropriate as investors should monitor the successful regulatory clearances and commercialization of new products in 2026 to assess the company's ability to return to sustained profitable growth.

Keywords

OraSure Technologies, OSUR, Diagnostics, Sample Management, HIV Self-Test, Chlamydia Gonorrhoeae Test, Colli-Pee, FDA Clearance, Q4 2025 Earnings, Financial Results, Molecular Diagnostics, At-Home Testing, STI Testing, Healthcare Technology, Biotechnology, Medical Devices